The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs presenting huge challenges to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
